evodiamine has been researched along with Leucocythaemia in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dong, F; Liu, X; Luan, C; Luan, S; Shao, H; Sun, C; Zhang, G | 1 |
| Bligh, SW; Hartley, JA; Hartley, JM; Pan, X; Wang, Z; White, KN | 1 |
2 other study(ies) available for evodiamine and Leucocythaemia
| Article | Year |
|---|---|
Evodiamine inhibits the proliferation of leukemia cell line K562 by regulating peroxisome proliferators-activated receptor gamma (PPARĪ³) pathway.
Topics: Anilides; Apoptosis; Cell Cycle; Cell Proliferation; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p21; Gene Expression Regulation, Neoplastic; Humans; K562 Cells; Leukemia; PPAR gamma; Quinazolines | 2016 |
Evodiamine, a dual catalytic inhibitor of type I and II topoisomerases, exhibits enhanced inhibition against camptothecin resistant cells.
Topics: Antineoplastic Agents, Phytogenic; Camptothecin; Cell Line, Tumor; Cell Proliferation; DNA Damage; DNA Topoisomerases; DNA Topoisomerases, Type I; DNA Topoisomerases, Type II; Drug Resistance, Neoplasm; Drugs, Chinese Herbal; Evodia; Fruit; Humans; Inhibitory Concentration 50; Leukemia; Phytotherapy; Quinazolines; Topoisomerase I Inhibitors; Topoisomerase II Inhibitors; Topoisomerase Inhibitors | 2012 |